

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-188002	Application No. 10/665,240
Information Disclosure Statement by Applicant <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small>		Applicant Tommy Ekstrom			
		Filing Date September 19, 2003	Group Art Unit 1617		

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/KC/	A1	Arvidsson <i>et al.</i> , "Inhaled formoterol during one year in asthma: a comparison with salbutamol," <i>Eur Respir J</i> , 4:1168-1173, 1991.					
/KC/	A2	Aubier <i>et al.</i> , "Salmeterol/Fluticasone propionate (50/500 µg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma," <i>Respir. Med.</i> 93:876-884, 1999.					
/KC/	A3	Bartow <i>et al.</i> , "Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," <i>Drugs</i> , 55(2):303-322, 1998.					
/KC/	A4	Bond, "A strategy that works," <i>New Zealand Medical Journal</i> , p. 369, 28 August 1991.					
/KC/	A5	Corren <i>et al.</i> , "Twelve-Week, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Tolerability of Budesonide and Formoterol in One Metered-Dose Inhaler Compared with Budesonide Alone and Formoterol Alone in Adolescents and Adults with Asthma," <i>Clinical Therapeutics</i> , 29(5):823-843, 2007.					
/KC/	A6	Costain <i>et al.</i> , "Guidelines for management of asthma in adults: I—chronic persistent asthma," <i>BMJ</i> , 301:651-653, 1990.					
/KC/	A7	Ebdon <i>et al.</i> , "Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (500 µg/day) and budesonide (1600 µg/day), for chronic asthma," <i>Thorax</i> , 41:869-874, 1986.					
/KC/	A8	"FDA recommends easier-to-take asthma drug" <i>Florida Today</i> , Associate Press, November 24, 1999.					
/KC/	A9	"Foradil: Fast relief that lasts," Ciba-Geigy Limited, Switzerland, Medical and Pharmaceutical Information, 1993					
/KC/	A10	Hekking <i>et al.</i> presentation, "Efficacy and tolerability of inhaled formoterol compared with inhaled salbutamol over three months", Symposium held during the 8 th congress of the European Society of Pneumology, Freiberg, Germany, September 1989.					
/KC/	A11	Jackson <i>et al.</i> , "Benefit-Risk Assessment of Long-Acting β ₂ -Agonists in Asthma," <i>Drug Safety</i> , 27(4):243-270, 2004.					
/KC/	A12	Kesten <i>et al.</i> , "A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable Asthma," <i>Am Rev Respir Dis</i> , 144:622-625, 1991.					
/KC/	A13	Kumar <i>et al.</i> , "Transient Effect of Inhaled Fluticasone on Airway Mucosal Blood Flow in Subjects with and without Asthma," <i>Am J Respir Crit Care Med</i> , 161:918-921, 2000.					
/KC/	A14	Lampa <i>et al.</i> , "Antitracheobronchospastic Interaction <i>In Vitro</i> and <i>In Vivo</i> between Salbutamol and Flunisolide," <i>Drugs Exptl. Clin. Res.</i> , XI(9):653-658, 1985.					

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-188002	Application No. 10/665,240
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Tommy Ekstrom		
		Filing Date September 19, 2003	Group Art Unit 1617	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/KC/	A15	McDonald <i>et al.</i> , "Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma," <i>Curr. Med. Res. Opin.</i> , 11(2):116-122, 1988.
/KC/	A16	McFadden, "Inhaled Glucocorticoids and Acute Asthma: Therapeutic Breakthrough or Nonspecific Effect?," <i>Am J Respir Crit Care Med</i> , 157:677-678, 1998.
/KC/	A17	Monthly Index of Medical Specialties (MIMS), Asthma, COPD, September 2007.
/KC/	A18	Monthly Index of Medical Specialties (MIMS), Bronchodilators and anti-inflammatories, December 1991.
/KC/	A19	Monthly Index of Medical Specialties (MIMS), Respiratory System, December, 1991.
/KC/	A20	Moore <i>et al.</i> , "Long-acting Inhaled β_2 -Agonists in Asthma Therapy," <i>Chest</i> , 113:1095-1108, 1998.
/KC/	A21	Nyholm <i>et al.</i> , "Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma," <i>Eur J Respir Dis</i> , 65:339-345, 1984.
/KC/	A22	Rabe <i>et al.</i> , "The challenge of long-acting β -adrenoceptor agonists," <i>Respiratory Medicine</i> , 85:5-9, 1991.
/KC/	A23	Rabe <i>et al.</i> , "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study," <i>Lancet</i> , 368:744-753, 2006.
/KC/	A24	Rabe <i>et al.</i> , "Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma," <i>Chest</i> , 129:246-256, 2006.
/KC/	A25	Rees, " β_2 Agonists and asthma," <i>BMJ</i> , 302:1166-1167, 1991.
/KC/	A26	Rodrigo <i>et al.</i> , "Inhaled Flunisolide for Acute Severe Asthma," <i>Am J Respir Crit Care Med</i> , 157:698-703, 1998.
/KC/	A27	Rodrigo <i>et al.</i> , "Acute Asthma in Adults: A Review," <i>Chest</i> , 125:1081-1102, 2004.
/KC/	A28	Sears <i>et al.</i> , "Regular inhaled beta-agonist treatment in bronchial asthma," <i>Lancet</i> , 336:1391-1396, 1990.
/KC/	A29	Shepherd <i>et al.</i> , "Regular Versus Symptomatic Aerosol Bronchodilator Treatment of Asthma", <i>Br. J. Dis. Chest</i> , Vol. 75, pages 215-217 (1981).
/KC/	A30	Tan <i>et al.</i> , "Systemic Corticosteroid Rapidly Reverses Bronchodilator Subsensitivity induced by Formoterol in Asthmatic Patients", <i>Am. J. Respiratory and Critical Care Medicine</i> , 156:28-35, 1997.
/KC/	A31	The Dialog Corporation, "Formoterol launched in Switzerland", Accession No: S002557609000, 10/31/1990.
/KC/	A32	The Merck Manual of Diagnosis and Therapy, 16 th edition, 1992, page 653.
/KC/	A33	Trechsel, "Foradil in medical practice: 7 case studies," <i>British J. Pharmacol.</i> , Vol. 83 (1984).
/KC/	A34	Waalkens <i>et al.</i> , "Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow," <i>Thorax</i> , 46:499-503, 1991.
/KC/	A35	Wallin <i>et al.</i> , "Formoterol, a new long acting beta2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma," <i>Thorax</i> , 45:259-261, 1990.

Examiner Signature /Kendra Carter/	Date Considered 09/05/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	